![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 1, 2024
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the 2024 ASCO Annual Meeting
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
May 1, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 9, 2024
A new trial in glioblastoma; leadership transitions; upcoming Group Meeting highlights
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
March 7, 2024
Big data projects near activation; APP Working Group builds momentum; ECOG-ACRIN welcomes Winn CILA scholar
March 7, 2024
ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
March 7, 2024
This cancer care delivery study aims to provide out-of-pocket cost estimates and remote counseling to assist patients in navigating the financial aspects of cancer treatment
March 7, 2024
Dr. Marshall's research focuses on the genetics of prostate cancer, as well as clonal hematopoiesis, a risk factor for cardiovascular disease that may be relevant to prostate cancer